Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 21-Aug-24 4:01 PM View:  | Ando Goran Director | Eyepoint Pharmaceuticals, I... (EYPT) | 21-Aug-24 | Private Purchase | 5,000 | $7.95 | $39,750.00 | 61% 8.15K to 13.15K | |
| 21-Aug-24 4:32 PM View: | Dicicco Wendy F Director | Eyepoint Pharmaceuticals, I... (EYPT) | 20-Aug-24 | Private Purchase | 2,567 | $7.79 | $19,996.90 | 35% 7.4K to 9.97K | |
| 21-Aug-24 4:01 PM View: | Zaderej Karen L. Director | Eyepoint Pharmaceuticals, I... (EYPT) | 19-Aug-24 | Private Purchase | 12,500 | $7.98 | $99,750.00 | 312% 4.0K to 16.5K | |
| 20-Aug-24 4:04 PM View: | Lurker Nancy Director | Eyepoint Pharmaceuticals, I... (EYPT) | 16-Aug-24 | Private Purchase | 3,173 | $7.88 | $25,003.20 | 1% 221.35K to 224.52K | |
| 16-Jul-24 4:24 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 12-Jul-24 | Option Sale | 9,775 | $10.06 | $98,376.60 | (73%) 13.47K to 3.7K | |
| 16-Jul-24 4:24 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 12-Jul-24 | Option Exercise | 9,775 | $3.34 | $32,646.50 | 264% 3.7K to 13.47K | |
| 16-Jul-24 4:24 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 12-Jul-24 | Sale | 1,850 | $10.06 | $18,618.60 | (50%) 3.7K to 1.85K | |
| 12-Jul-24 5:00 PM View: | Zaderej Karen L. Director | Eyepoint Pharmaceuticals, I... (EYPT) | 11-Jul-24 | Option Exercise | 2,000 | -- | -- | 100% 2.0K to 4.0K | |
| 12-Jul-24 5:04 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 10-Jul-24 | Option Exercise | 16,666 | -- | -- | 32% 51.92K to 68.59K | |
| 12-Jul-24 5:03 PM View: | Lurker Nancy Executive Vice Chair Director | Eyepoint Pharmaceuticals, I... (EYPT) | 10-Jul-24 | Option Exercise | 11,111 | -- | -- | 5% 210.24K to 221.35K | |
| 12-Jul-24 5:04 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 10-Jul-24 | Payment of Exercise | 8,059 | $8.69 | $70,032.70 | (12%) 68.59K to 60.53K | |
| 25-Jun-24 4:16 PM View: | Adamis Anthony P Director | Eyepoint Pharmaceuticals, I... (EYPT) | 23-Jun-24 | Option Exercise | 2,000 | -- | -- | 100% 2.0K to 4.0K | |
| 04-Jun-24 4:28 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 03-Jun-24 | Option Exercise | 9,775 | $3.34 | $32,646.50 | 176% 5.55K to 15.32K | |
| 04-Jun-24 4:28 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 03-Jun-24 | Option Sale | 9,775 | $10.30 | $100,655.00 | (64%) 15.32K to 5.55K | |
| 04-Jun-24 4:28 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 03-Jun-24 | Sale | 1,850 | $10.30 | $19,049.80 | (33%) 5.55K to 3.7K | |
| 28-May-24 10:00 PM View: | Elston George Chief Financial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-May-24 | Payment of Exercise | 3,627 | $11.16 | $40,477.30 | (7%) 51.11K to 47.48K | |
| 28-May-24 10:00 PM View: | Elston George Chief Financial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-May-24 | Option Exercise | 7,500 | -- | -- | 17% 43.61K to 51.11K | |
| 16-May-24 5:19 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 14-May-24 | Sale | 1,850 | $12.65 | $23,400.70 | (25%) 7.4K to 5.55K | |
| 16-May-24 5:19 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 14-May-24 | Option Exercise | 9,775 | $3.34 | $32,646.50 | 132% 7.4K to 17.18K | |
| 16-May-24 5:19 PM View: | Guyer David R Director | Eyepoint Pharmaceuticals, I... (EYPT) | 14-May-24 | Option Sale | 9,775 | $12.65 | $123,644.00 | (57%) 17.18K to 7.4K | |
| 08-May-24 4:23 PM View: | Cormorant Asset Management,... 10% Owner | Eyepoint Pharmaceuticals, I... (EYPT) | 06-May-24 | Market Purchase | 850,000 | $11.86 | $10,081,700.00 | 11% 7.47M to 8.32M | 6% |
| 22-Apr-24 4:00 PM View: | Cormorant Asset Management,... 10% Owner | Eyepoint Pharmaceuticals, I... (EYPT) | 18-Apr-24 | Purchase | 581,765 | $18.03 | $10,489,400.00 | 8% 6.89M to 7.47M | |
| 02-Apr-24 5:27 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 30-Mar-24 | Option Exercise | 50,404 | -- | -- | 119% 42.22K to 92.63K | |
| 02-Apr-24 5:27 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 30-Mar-24 | Payment of Exercise | 25,546 | $20.67 | $528,036.00 | (28%) 92.63K to 67.08K | |
| 28-Feb-24 4:46 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 27-Feb-24 | Gift | 2,500 | -- | -- | 5% 51.92K to 54.42K | |
| 28-Feb-24 4:46 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 27-Feb-24 | Gift | 2,500 | -- | -- | (5%) 54.42K to 51.92K | |
| 22-Feb-24 5:08 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 20-Feb-24 | Gift | 20,000 | -- | -- | (28%) 71.92K to 51.92K | |
| 22-Feb-24 5:08 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 20-Feb-24 | Gift | 20,000 | -- | -- | 39% 51.92K to 71.92K | |
| 13-Feb-24 5:40 PM View: | Lurker Nancy Executive Vice Chair Director | Eyepoint Pharmaceuticals, I... (EYPT) | 13-Feb-24 | Gift | 74,681 | -- | -- | 36% 210.24K to 284.92K | |
| 13-Feb-24 5:40 PM View: | Lurker Nancy Executive Vice Chair Director | Eyepoint Pharmaceuticals, I... (EYPT) | 13-Feb-24 | Gift | 74,681 | -- | -- | (26%) 284.92K to 210.24K | |
| 13-Feb-24 5:40 PM View: | Lurker Nancy Executive Vice Chair Director | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Payment of Exercise | 14,943 | $28.80 | $430,358.00 | (7%) 225.18K to 210.24K | |
| 13-Feb-24 5:40 PM View: | Lurker Nancy Executive Vice Chair Director | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Option Exercise | 37,534 | -- | -- | 20% 187.65K to 225.18K | |
| 13-Feb-24 5:38 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Option Exercise | 9,967 | -- | -- | 26% 38.6K to 48.57K | |
| 13-Feb-24 5:37 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Payment of Exercise | 3,533 | $28.80 | $101,750.00 | (6%) 55.45K to 51.92K | |
| 13-Feb-24 5:39 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Payment of Exercise | 5,083 | $28.80 | $146,390.00 | (11%) 47.3K to 42.22K | |
| 13-Feb-24 5:37 PM View: | Duker Jay S. President and CEO Director | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Option Exercise | 11,967 | -- | -- | 28% 43.49K to 55.45K | |
| 13-Feb-24 5:38 PM View: | Elston George Chief Financial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Option Exercise | 10,800 | -- | -- | 30% 36.0K to 46.8K | |
| 13-Feb-24 5:38 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Payment of Exercise | 3,656 | $28.80 | $105,293.00 | (8%) 48.57K to 44.92K | |
| 13-Feb-24 5:39 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Option Exercise | 10,800 | -- | -- | 30% 36.51K to 47.3K | |
| 13-Feb-24 5:38 PM View: | Elston George Chief Financial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 09-Feb-24 | Payment of Exercise | 3,192 | $28.80 | $91,929.60 | (7%) 46.8K to 43.61K | |
| 05-Feb-24 5:15 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 02-Feb-24 | Option Exercise | 209 | $11.47 | $2,397.23 | < 1% 37.96K to 38.17K | |
| 05-Feb-24 5:15 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 02-Feb-24 | Option Sale | 209 | $28.49 | $5,954.41 | (< 1%) 38.17K to 37.96K | |
| 29-Jan-24 5:54 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 26-Jan-24 | Option Sale | 26,017 | $25.38 | $660,370.00 | (41%) 63.98K to 37.96K | |
| 30-Jan-24 4:53 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 26-Jan-24 | Option Exercise | 49,325 | $13.06 | $644,047.00 | 135% 36.51K to 85.83K | (3%) |
| 30-Jan-24 4:53 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 26-Jan-24 | Private Option Sale | 49,325 | $25.66 | $1,265,540.00 | (57%) 85.83K to 36.51K | |
| 29-Jan-24 5:54 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 26-Jan-24 | Option Exercise | 26,017 | $6.82 | $177,398.00 | 69% 37.96K to 63.98K | |
| 29-Jan-24 5:51 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-Jan-24 | Option Exercise | 600 | $13.02 | $7,809.00 | 2% 36.51K to 37.1K | (3%) |
| 29-Jan-24 5:51 PM View: | Paggiarino Dario A. Chief Medical Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-Jan-24 | Private Option Sale | 600 | $25.00 | $15,000.00 | (2%) 37.1K to 36.51K | |
| 26-Jan-24 5:03 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-Jan-24 | Option Exercise | 600 | $8.08 | $4,848.00 | 2% 37.96K to 38.56K | |
| 26-Jan-24 5:03 PM View: | Jones David Scott SVP & Chief Commercial Officer | Eyepoint Pharmaceuticals, I... (EYPT) | 25-Jan-24 | Option Sale | 600 | $25.00 | $15,000.00 | (2%) 38.56K to 37.96K |
